

## REMARKS/ARGUMENTS

Claims 21-25, 27-33 and 35-39 are pending in the present application.

Claims 21-25, 27-33 and 35-39 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. Claims 21 and 29 are the only independent claims. Claim 21 recites a genus of polyethylene glycol-containing compounds, which are cleared by an anti-polyethylene glycol antibody. Claim 29 recites that the polyethylene glycol-containing compound comprises a tumor targeting moiety and a moiety for activating an anti-tumor prodrug.

The Examiner states that present specification fails to provide a representative number of polyethylene glycol-containing compounds that encompass the recited genus of polyethylene glycol-containing compounds. In response, claims 21 and 29 have been amended to recite that the compounds are limited to those capable of binding to an anti-polyethylene glycol monoclonal antibody that is produced by immunizing a mouse with a RH1- $\beta$ G-PEG conjugate, and that the anti-polyethylene glycol monoclonal antibody is limited to that which is produced by immunizing a mouse with a RH1- $\beta$ G-PEG conjugate.

The present amendments to claims 21 and 29 are fully supported in the present specification at pages 8 to 9, and at pages 16 to 51. Specifically, the specification at pages 17-20 discloses the method of producing the RH1- $\beta$ G-PEG conjugate. The specification at pages 20-21 discloses the method of generating monoclonal antibodies by immunizing mice with the RH1- $\beta$ G-PEG conjugate. The specification at pages 36-40 discloses the ability of the anti-PEG monoclonal antibody to clear PEG-containing compounds. The specification at pages 43-51 discloses the ability of a PEG-containing compound containing a tumor targeting moiety and a moiety for activating an anti-tumor prodrug to localize onto the tumor; the ability of the anti-


PEG monoclonal antibody to accelerate the clearance of the PEG-containing compound from the blood serum; and the ability of the prodrug to interact with the PEG-containing compound that is localized onto the tumor to treat the tumor.

Accordingly, it is respectfully submitted that the rejection of claims 21-25, 27-33 and 35-39 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement, be withdrawn.

If any additional fees or charges are required at this time, they may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

Respectfully submitted,  
COHEN, PONTANI, LIEBERMAN & PAVANE LLP

By

  
Kent H. Cheng  
Reg. No. 33,849  
551 Fifth Avenue, Suite 1210  
New York, New York 10176  
(212) 687-2770

Dated: July 24, 2006